Day 1 - Wednesday, 25 May 2016
Meeting category
Date(s)
25 May 2016 - 27 May 2016
Program Language
English
Location
Rome,
Italy
Meeting type
Live Meeting
Organizer
European Meeting on HIV & Hepatitis 2016
Related Enduring Materials
Enduring Materials
-
HIV in Europe 2020 – what will it look like?
Session 1: Early ARV treatment: start early, but not too early -
Invited lecture: Life-long therapy
Georg Behrens, MD, PhD
Medical School Hannover, Germany
Abstract presentations
Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance
Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study
Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects
Session 2: Spread of HIV drug resistance -
Abstract presentations
Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population proportions
Transmission of HIV drug resistance mutations varies regionally in Europe
Dr. M. Hofstra
-
Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen
Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R
Session 3: Abstract session - HBV- related -
HBV cure - Educational lecture in collaboration with ESAR
Abstract presentations
Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases
Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death
HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression
Session 4: Implementation of PrEP in Europe -
Roadblocks to implementation
Two cases of HIV drug resistance arising after PrEP
Richard Harrigan, PhD, MD
BC Centre for Excellence in HIV/AIDS, Canada
Day 2 - Thursday, 26 May 2016
Session 5: Special session - maintenance therapy -
Maintenance Therapy - What is known
Maintenance Therapy - What is the scientific/ virological rational
Maintenance Therapy - What is the Future
Day 2 - Friday, 27 May 2016
Session 6: Remaining challenges in the optimal use of boosted Pis -
Anna Maria Geretti, MD, PhD, FRCPath
PI are obsolete in first line
University of Rome, Italy / King's College London, United Kingdom
PI remain important options for first line
Improving PI drug resistance scores
Session 7: HIV cure strategies -
Diagnostic Assays
Javier Martinez-Picado, PhD
Irsi Caixa Foundation, Spain
Abstract presentations
Ex vivo determination of stem cell transplantation graft-versus-HIV reservoir effects
Clonal Integration Site Frequency and Replication Competent Virus in Patients on ART
Dr. L. Vanderkerckhove
-
Boston Project
Tim Henrich, MD
UCSF, USA
Abstract presentations
Viral dynamics and post-mortem analysis of HIV-1 Reservoir after Allogeneic Transplantation using Stem Cells with a nonfunctional CCR5 (CCR5?32) co-receptor
Dr. K. Bosman
-
Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation
Dr. E. Knops
-
Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation.
Overview
We are pleased to look back on the 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, held on 25 - 27 May 2016 in Rome, Italy. With nearly 300 participants from 41 countries, it was one of the most successful editions of this meeting to date.
The Organizing Committee and the organizing secretariat would like to thank the invited speakers and all participants for their contribution to this meeting! In particular we would like to thank our sponsors ViiV Healthcare and Gilead Sciences. Without their financial contribution this meeting would not be possible.
Yours sincerely,
Chairs 2016
General Information
Meeting Objectives
This meeting aims to:
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies
Language
Related Programs
